aTyr outlines a new Phase 3 sarcoidosis study after FDA discussions
aTyr Pharma ($ATYR) said it had aligned with the FDA on the design of a Phase 3 study of efzofitimod in pulmonary sarcoidosis patients with restrictive lung disease. The planned trial would enroll 372 patients and compare treatment with placebo over 54 weeks. Its primary endpoint would assess forced vital capacity at week 48, with patient-reported measures among the secondary outcomes. The design draws on findings from the company’s earlier development program, but it is not a new demonstration
0